Literature DB >> 26370175

Cathelicidin Antimicrobial Peptide: A Novel Regulator of Islet Function, Islet Regeneration, and Selected Gut Bacteria.

Lynley D Pound1, Christopher Patrick1, Chandra E Eberhard1, Walid Mottawea2, Gen-Sheng Wang1, Turki Abujamel3, Roxanne Vandenbeek1, Alain Stintzi3, Fraser W Scott4.   

Abstract

Cathelicidin antimicrobial peptide (CAMP) is a naturally occurring secreted peptide that is expressed in several organs with pleiotropic roles in immunomodulation, wound healing, and cell growth. We previously demonstrated that gut Camp expression is upregulated when type 1 diabetes-prone rats are protected from diabetes development. Unexpectedly, we have also identified novel CAMP expression in the pancreatic β-cells of rats, mice, and humans. CAMP was present even in sterile rat embryo islets, germ-free adult rat islets, and neogenic tubular complexes. Camp gene expression was downregulated in young BBdp rat islets before the onset of insulitis compared with control BBc rats. CAMP treatment of dispersed islets resulted in a significant increase in intracellular calcium mobilization, an effect that was both delayed and blunted in the absence of extracellular calcium. Additionally, CAMP treatment promoted insulin and glucagon secretion from isolated rat islets. Thus, CAMP is a promoter of islet paracrine signaling that enhances islet function and glucoregulation. Finally, daily treatment with the CAMP/LL-37 peptide in vivo in BBdp rats resulted in enhanced β-cell neogenesis and upregulation of potentially beneficial gut microbes. In particular, CAMP/LL-37 treatment shifted the abundance of specific bacterial populations, mitigating the gut dysbiosis observed in the BBdp rat. Taken together, these findings indicate a novel functional role for CAMP/LL-37 in islet biology and modification of gut microbiota.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26370175     DOI: 10.2337/db15-0788

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis.

Authors:  Kohei Hasegawa; Jonathan M Mansbach; Nadim J Ajami; Joseph F Petrosino; Robert J Freishtat; Stephen J Teach; Pedro A Piedra; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2016-11-12       Impact factor: 10.793

2.  Changes in the Coexpression of Innate Immunity Genes During Persistent Islet Autoimmunity Are Associated With Progression of Islet Autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  Patrick M Carry; Kathleen Waugh; Lauren A Vanderlinden; Randi K Johnson; Teresa Buckner; Marian Rewers; Andrea K Steck; Ivana Yang; Tasha E Fingerlin; Katerina Kechris; Jill M Norris
Journal:  Diabetes       Date:  2022-09-01       Impact factor: 9.337

Review 3.  Replicative capacity of β-cells and type 1 diabetes.

Authors:  Diane Saunders; Alvin C Powers
Journal:  J Autoimmun       Date:  2016-04-28       Impact factor: 7.094

4.  Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells.

Authors:  John Gubatan; Gillian A Mehigan; Fernando Villegas; Shuji Mitsuhashi; Maria Serena Longhi; Grace Malvar; Eva Csizmadia; Simon Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

5.  Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.

Authors:  Aran Singanayagam; Nicholas Glanville; Leah Cuthbertson; Nathan W Bartlett; Lydia J Finney; Elena Turek; Eteri Bakhsoliani; Maria Adelaide Calderazzo; Maria-Belen Trujillo-Torralbo; Joseph Footitt; Phillip L James; Peter Fenwick; Samuel V Kemp; Thomas B Clarke; Jadwiga A Wedzicha; Michael R Edwards; Miriam Moffatt; William O Cookson; Patrick Mallia; Sebastian L Johnston
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

6.  Immunomodulation and effects on microbiota after in ovo administration of chicken cathelicidin-2.

Authors:  Tryntsje Cuperus; Marina D Kraaij; Aldert L Zomer; Albert van Dijk; Henk P Haagsman
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

Review 7.  The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus.

Authors:  You Lv; Xue Zhao; Weiying Guo; Ying Gao; Shuo Yang; Zhuo Li; Guixia Wang
Journal:  J Diabetes Res       Date:  2018-05-07       Impact factor: 4.011

8.  Dysregulated liver lipid metabolism and innate immunity associated with hepatic steatosis in neonatal BBdp rats and NOD mice.

Authors:  D Serrano; J A Crookshank; B S Morgan; R W Mueller; M-F Paré; L Marandi; P Poussier; F W Scott
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

9.  LL-37 stimulates the functions of adipose-derived stromal/stem cells via early growth response 1 and the MAPK pathway.

Authors:  Yoolhee Yang; Hyunju Choi; Mira Seon; Daeho Cho; Sa Ik Bang
Journal:  Stem Cell Res Ther       Date:  2016-04-19       Impact factor: 6.832

10.  Elafin inhibits obesity, hyperglycemia, and liver steatosis in high-fat diet-treated male mice.

Authors:  Jiani Wang; Christina Ortiz; Lindsey Fontenot; Riya Mukhopadhyay; Ying Xie; Ivy Ka Man Law; David Q Shih; S Anjani Mattai; Zhaoping Li; Hon Wai Koon
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.